Literature DB >> 11083631

Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus.

T Chiller1, K Farrokhshad, E Brummer, D A Stevens.   

Abstract

There have been several reports that the activity of echinocandin antifungal agents is not affected or decreased in the presence of human sera. It is known that these drugs are bound >80% in animal and human sera. The activity of the echinocandin caspofungin (MK-0991), a 1,3-beta-D-glucan synthase inhibitor, against Aspergillus fumigatus with and without human sera was studied. Conidia of A. fumigatus in microtest plate wells formed germlings after overnight culture in RPMI 1640. Caspofungin was then added with or without serum, and the germlings were incubated at 37 degrees C for 24 h. Human serum (5%) in RPMI 1640 alone did not significantly inhibit the growth of A. fumigatus in vitro. Caspofungin in RPMI 1640 exhibited dose-dependent inhibition, with concentrations of 0.1 and 0.05 microg/ml inhibiting 24.9% +/- 10.4% and 11.7% +/- 3.6%, respectively (n = 10; P < 0.01). The addition of 5% human serum to caspofungin at 0.1 or 0.05 microg/ml increased the inhibition to 78.6% +/- 5.8% or 58.3% +/- 19.2%, respectively (n = 10; P < 0.01 versus controls and versus the drug without serum). Lower concentrations of serum also potentiated drug activity. The effect of human sera was further seen when using caspofungin that had lost activity (e.g., by storage) against A. fumigatus at 0.1 microg/ml. Inactive caspofungin alone demonstrated no significant inhibition of hyphal growth, whereas the addition of 5% human serum to the inactive drug showed 83% +/- 16.5% inhibition (n = 5; P < 0. 01). The restoration of activity of caspofungin was seen at concentrations as low as 0.05% human serum. In contrast to prior reports, this study suggests that human serum acts synergistically with caspofungin to enhance its inhibitory activity in vitro against A. fumigatus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083631      PMCID: PMC90196          DOI: 10.1128/AAC.44.12.3302-3305.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus.

Authors:  E Brummer; S D Chauhan; D A Stevens
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

2.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors:  R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.

Authors:  S Vora; S Chauhan; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity.

Authors:  F Nassar; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum.

Authors:  E Brummer; K Kamei; M Miyaji
Journal:  Mycopathologia       Date:  1998       Impact factor: 2.574

8.  A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT).

Authors:  T Meshulam; S M Levitz; L Christin; R D Diamond
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

  8 in total
  11 in total

1.  What's New in Antifungals?

Authors:  John M. Valgus
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

2.  Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae.

Authors:  Petros Ioannou; Aggeliki Andrianaki; Tonia Akoumianaki; Irene Kyrmizi; Nathaniel Albert; David Perlin; George Samonis; Dimitrios P Kontoyiannis; Georgios Chamilos
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

3.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

4.  Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Authors:  Emilia Cantón; Javier Pemán; Macrina Sastre; Mónica Romero; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

6.  In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; Destiny Molina; Marcos Olivo; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

7.  Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures.

Authors:  Melanie T Cushion; Margaret S Collins
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

8.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation.

Authors:  Heather L Van Epps; Marta Feldmesser; Eric G Pamer
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes.

Authors:  U Frank; M Greiner; I Engels; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.